RecruitingNCT07758816

Advancing Integrated Therapies for Gaucher Disease

Advancing Integrated Therapies for Gaucher Disease: Neuronopathic Innovation and Combination Strategies for Refractory Skeletal Disease

Sponsor

Yale University

Enrollment

30 participants

Start Date

May 6, 2026

Study Type

OBSERVATIONAL

Conditions

Gaucher Disease

Summary

The purpose of this study is to better understand the natural history, clinical outcomes, and biological features of Gaucher disease in patients receiving standard medical care

Eligibility

Min Age: 3 MonthsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with gaucher disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 3 Months to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.